REGQUALITYREVIEW

Evidence for systems that carry regulated work.

Provider capability evidence record

Kivo and Controlled Documents

What the current official record does—and does not—establish about Kivo for controlled documents.

What the source record establishes

Kivo provides cloud regulatory document, content, process, submission-planning, dossier, and correspondence management for emerging life-sciences sponsors and service providers.

The maintained taxonomy connects that documented market position to Controlled Documents. This page keeps the claim at the level supported by the source: Kivo presents an offering relevant to this work. It does not silently convert a product description into an observed result, a conformity finding, or a universal recommendation.

Current fit signal: Emerging pharmaceutical, biotechnology, and device teams seeking controlled regulatory content, collaboration, submission preparation, and implementation support without a large enterprise RIM program.

What controlled documents means in this market

Controlled Documents should be evaluated as an operating chain rather than a feature label. The chain begins with a named business condition and governed input, passes through configured logic and accountable review, produces an output or action, handles exceptions, and preserves enough evidence for another person to reconstruct the decision later.

Quality-system governance and controlled content

Risk that policies, procedures, specifications, instructions, forms, records, roles, and management oversight do not remain approved, current, available, attributable, and connected to the regulated work they govern.

Computerized systems, validation, and data integrity

Risk that a quality or regulatory system is not fit for intended use, remains insufficiently controlled through change, or cannot preserve complete, consistent, accurate, attributable, legible, contemporaneous, original, and available records across its lifecycle.

Submission content and technical conformance

Risk that regulated content cannot be planned, authored, approved, assembled, validated, transmitted, received, and maintained in the correct format and lifecycle for the relevant authority and procedure.

Who owns the decision

A capability can be technically available while operating ownership remains fragmented. The evaluation should name the person accountable for policy or business interpretation, the person responsible for configuration and data, the reviewer with authority to resolve exceptions, the approver of release or action, and the owner of monitoring and retirement.

Kivo should be asked to distinguish what the product decides, what it recommends, what it merely displays, and what remains an organizational judgment. A generic “human in the loop” statement is inadequate unless the human has time, context, evidence, and authority.

Evidence package to request from Kivo

  • The exact product and package proposed, with a dated list of native, integrated, partner, service, and customer-owned components.
  • A representative input set, its authoritative source, permitted use, quality checks, and version history.
  • The configured workflow from intake through review, exception, approval, action, retention, and export.
  • A normal result and at least two difficult exceptions, including one caused by missing or contradictory evidence.
  • Role and access definitions for configuration, review, approval, override, monitoring, and administration.
  • An implementation map naming integrations, migrations, customer work, provider work, services, test environments, and release gates.
  • A retained decision record showing source, logic or model version, user action, timestamps, disposition, and downstream effect.
  • A measurement plan with baseline, observation period, population, error threshold, exclusions, and stop condition.

Demonstration script

  1. Which exact Kivo product, edition, module, service, and geography support controlled documents?
  2. What source data, content, rules, and integrations does Kivo require before the workflow can begin?
  3. Where does human judgment enter, and which person can approve, reject, override, or stop the controlled documents workflow?
  4. How does the proposed configuration handle missing data, conflicting evidence, changed rules, and an expired or revoked approval?
  5. What record preserves inputs, transformations, user actions, exceptions, outputs, timestamps, and downstream consequences?
  6. Which parts are native, partner-delivered, service-delivered, or left to the customer?
  7. What can be exported at implementation, audit, renewal, migration, and exit?
  8. Which observation would falsify the current fit hypothesis for Kivo?
  9. Which content and record types are authoritative in the proposed system, and which remain in another repository?
  10. How are effective dates, supersession, periodic review, distribution, controlled copies, and archival governed?
  11. How does a document change identify affected training, forms, processes, products, markets, and open records?
  12. Can the organization export readable content, metadata, audit trails, relationships, and signatures without vendor assistance?

Use the same scenario with every finalist. Let the provider explain differences in architecture, but keep the business condition, required evidence, exception, and expected decision record constant. That makes the evaluation comparable without pretending that unlike products should receive one synthetic score.

Failure modes and boundary conditions

  • a polished normal path that hides missing or contradictory evidence
  • an automation step that exceeds the user's authority
  • a score or generated explanation that cannot be traced to a source and version
  • an exception that disappears into email or an unexportable activity log

Kivo states that publishing is handed off to specialist tools or services; buyers should not infer native eCTD publishing. Public pages do not establish full global registration management, enterprise scale, or a customer's validated state.

A buyer should also distinguish absence of public evidence from evidence of absence. If Kivo has not publicly documented a required detail, the correct status is “not established in this review” until a current, attributable source or direct observation resolves it.

Authority and standards context

FDA drug CGMP

eQMS products organize records supporting drug CGMP processes, but software boundaries must align with manufacturing, laboratory, ERP, MES, and supplier systems. A feature list alone cannot establish that regulated processes are controlled.

Interpretation boundary: The regulation defines CGMP obligations, not a commercial eQMS specification. Buyers must map their own records and controls to applicable sections and connected systems.

This mapping identifies a workflow that may help organize evidence. It does not state that Kivo conforms to, complies with, or is certified against the authority.

ISO 13485:2016

The standard is a central organizing reference for medical-device QMS design and is incorporated into the U.S. QMSR. Buyers need systems that can express their own processes and evidence without treating a vendor template as the standard itself.

Interpretation boundary: ISO publishes the standard and does not certify organizations or software. The public ISO page summarizes scope; detailed requirements are in the licensed standard.

This mapping identifies a workflow that may help organize evidence. It does not state that Kivo conforms to, complies with, or is certified against the authority.

ICH Q10

Q10 provides an operating model that crosses organizational and software boundaries. An eQMS can support records and coordination, but buyers must test how the system connects monitoring, investigation, CAPA, change, knowledge, and management oversight.

Interpretation boundary: ICH Q10 is a quality-system model, not a software certification or prescribed workflow. Regulatory adoption and product-specific obligations must be checked in the relevant jurisdiction.

This mapping identifies a workflow that may help organize evidence. It does not state that Kivo conforms to, complies with, or is certified against the authority.

Comparable records to inspect

The following organizations also have current official positioning mapped to controlled documents. Inclusion is a research pathway, not a shortlist or claim of equivalence.

  • AmpleLogic — Integrated Quality And Regulatory Platform with documented positioning relevant to Controlled Documents
  • Arena QMS — Medical-Device Quality And Product-Lifecycle Platform with documented positioning relevant to Controlled Documents
  • AssurX — Configurable QMS With Life-Sciences Offering with documented positioning relevant to Controlled Documents
  • ComplianceQuest — Configurable QMS With Life-Sciences Offering with documented positioning relevant to Controlled Documents
  • Dot Compliance — Enterprise Life-Sciences EQMS with documented positioning relevant to Controlled Documents
  • Ennov — Integrated Quality And Regulatory Platform with documented positioning relevant to Controlled Documents

Official authority sources

The following primary authority pages support the standards context used in this record. They define an evaluation boundary; they do not endorse Kivo or establish product conformity.

FDA drug CGMP

Open the official authority source and confirm the current text, effective date, scope, and organization-specific applicability before relying on this mapping.

ISO 13485:2016

Open the official authority source and confirm the current text, effective date, scope, and organization-specific applicability before relying on this mapping.

ICH Q10

Open the official authority source and confirm the current text, effective date, scope, and organization-specific applicability before relying on this mapping.

Conditional conclusion

Kivo belongs in deeper evaluation for controlled documents when its documented regulatory content and document management operating model matches the buyer's real workflow, the proposed package contains the required components, and a representative test produces reviewable evidence through normal and exception paths. The conclusion should be reversed or narrowed when the product boundary, source data, authority mapping, integration burden, human decision rights, exportability, or measured result does not meet the stated approval conditions.

Official provider source: Kivo.

Record date: 2026-07-19T13:30:00.000Z. The date records the maintained source review, not an independent product test.

Editorial boundary: RegQuality Review is not a regulator, certification body, law firm, or validation authority. Its records support research and decision review; they do not establish compliance for an organization, system, release, configuration, or intended use.

Methodology · Submit a source-backed correction